Scarica l'app Stockscreener
0.6096
11.44%
0.0626
Pre-mercato:
.57
-0.0396
-6.50%
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
Ensysce Biosciences, Inc. Announces Director Resignation in April 2026 Form 8-K Filing - Minichart
Ensysce Biosciences director Curtis Rosebraugh resigns from board - Investing.com
Ensysce Biosciences Announces Board Member Curtis Rosebraugh Resignation - TipRanks
Board member Curtis Rosebraugh exits Ensysce Biosciences (NASDAQ: ENSC) - stocktitan.net
ENSC SEC FilingsEnsysce Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce Biosciences, Inc. — Business Overview, Risk Factors, Regulatory Approvals, and Intellectual Property Challenges 64 - Minichart
8-K: Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - moomoo.com
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - bitget.com
Smart Money: Will Ensysce Biosciences Inc benefit from geopolitical trendsWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Ensysce Biosciences (NASDAQ: ENSC) outlines abuse-resistant opioid pipeline - Stock Titan
ENSC: Net loss widened to $10.2 million in 2025; ongoing operations depend on new capital raises - TradingView
Ensysce Biosciences Reports Q4 and Full Year 2025 Results - National Today
Ensysce (NASDAQ: ENSC) advances PF614 programs as 2025 net loss hits $10.2M - stocktitan.net
Ensysce Biosciences Q4 net loss narrows to $2.8 mln - TradingView
Ensysce pushes abuse-deterrent opioid into late-stage testing - stocktitan.net
Ensysce Biosciences (NASDAQ: ENSC) director quits after opposing retention deals - stocktitan.net
Revenue Check: Does Ensysce Biosciences Inc meet Warren Buffetts criteria2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - stocktitan.net
ENSC Should I Buy - Intellectia AI
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
ENSC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Ensysce publishes phase 1 data on overdose-limiting opioid tech - Investing.com India
New opioid design limits drug release when too many pills are swallowed - Stock Titan
Promising Penny Stocks To Add to Your Watchlist – March 1st - Defense World
Dow Dips Over 600 Points; US Producer Prices Increase In January - Sahm
Top Penny Stocks To Follow TodayFebruary 27th - MarketBeat
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Ensysce Biosciences (ENSC) over sub-$1 minimum bid price - Stock Titan
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Corsicana Daily Sun
Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan
Market Overview: Is Ensysce Biosciences Inc subject to activist investor interest2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Corsicana Daily Sun
Drug developer Ensysce invited to 2026 pain and substance use research forums - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Can Ensysce Biosciences Inc. continue delivering strong returnsJuly 2025 Momentum & Reliable Entry Point Alerts - mfd.ru
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ensysce Biosciences files to sell 29.47M shares of common stock for holders - Intellectia AI
Why Ensysce Biosciences Inc. stock remains a top recommendationDip Buying & Free Community Consensus Stock Picks - mfd.ru
Why Ensysce Biosciences Inc. stock is a must watch in 2025Trade Entry Report & Daily Volume Surge Trade Alerts - mfd.ru
Is Ensysce Biosciences Inc. subject to activist investor interestQuarterly Performance Summary & Verified Technical Signals - mfd.ru
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):